Castillo Jorge, Perez Kimberly
The Warren Alpert Medical School of Brown University, Division of Hematology and Oncology, The Miriam Hospital, Providence, RI, USA.
J Blood Med. 2010;1:1-8. doi: 10.2147/JBM.S7284. Epub 2010 Feb 25.
Chronic lymphocytic leukemia (CLL) is an indolent but incurable disease. Despite the improvement of the available therapies, the management of heavily-treated CLL patients represents a challenge for modern practitioners. Ofatumumab is a second-generation, fully human anti-CD20 monoclonal antibody that has shown activity in CLL patients who have failed very effective therapies such as fludarabine, alemtuzumab and rituximab. Potential benefits of ofatumumab include powerful complement-dependent cytotoxicity, less immunogenicity, faster infusions and activity in resistant CLL patients. Recently, the FDA has approved ofatumumab for the treatment of CLL patients who have failed fludarabine and alemtuzumab-based regimens. The aim of this review is to summarize the current knowledge regarding pharmacology, mechanism of action, pre-clinical and clinical development, and the role of ofatumumab for the treatment of CLL patients who have failed previous therapies. Further research is necessary to further define the role of ofatumumab in the treatment of CLL.
慢性淋巴细胞白血病（CLL）是一种进展缓慢但无法治愈的疾病。尽管现有治疗方法有所改进，但对于接受过大量治疗的CLL患者的管理，仍是现代从业者面临的一项挑战。奥法木单抗是一种第二代全人源抗CD20单克隆抗体，在氟达拉滨、阿仑单抗和利妥昔单抗等非常有效的治疗失败的CLL患者中已显示出活性。奥法木单抗的潜在益处包括强大的补体依赖性细胞毒性、较低的免疫原性、更快的输注速度以及对耐药CLL患者的活性。最近，美国食品药品监督管理局（FDA）已批准奥法木单抗用于治疗对基于氟达拉滨和阿仑单抗的方案治疗失败的CLL患者。本综述的目的是总结关于奥法木单抗的药理学、作用机制、临床前和临床开发以及其在治疗既往治疗失败的CLL患者中的作用的当前知识。有必要进行进一步研究以进一步明确奥法木单抗在CLL治疗中的作用。
